Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989;27(Suppl 2):175S–180S. doi: 10.1111/j.1365-2125.1989.tb03479.x

Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors

B Waeber, L Juillerat-Jeanneret, J-F Aubert, M Schapira, J Nussberger, H R Brunner
PMCID: PMC1379745  PMID: 2669913

Abstract

1 Studies were performed in normal subjects and in rats to assess the effect of angiotensin converting enzyme (ACE) inhibition on the kallikrein-kinin system. As ACE is identical to kininase II, one of the enzymes physiologically involved in bradykinin degradation, bradykinin may be expected to accumulate during ACE inhibition.

2 A competitive antagonist of bradykinin was used to explore in unanaesthetized rats the contribution of circulating bradykinin to blood pressure control under ACE inhibition.

3 No evidence was found for a role of this vasodilating peptide in the blood pressure lowering effect of acute ACE inhibition.

4 The plasma activity of carboxypeptidase N (= kininase I), another pathway of bradykinin degradation, remained intact during a 1 week course of treatment with an ACE inhibitor in normal subjects. This therefore indicates that bradykinin formed during ACE inhibition can still be metabolized.

Keywords: bradykinin, kallikrein-kinin, captopril, ACE-inhibition, renin-angiotensin

Full text

PDF
175S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alving B. M., Hojima Y., Pisano J. J., Mason B. L., Buckingham R. E., Jr, Mozen M. M., Finlayson J. S. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med. 1978 Jul 13;299(2):66–70. doi: 10.1056/NEJM197807132990203. [DOI] [PubMed] [Google Scholar]
  2. Aubert J. F., Waeber B., Nussberger J., Vavrek R., Stewart J. M., Brunner H. R. Influence of endogenous bradykinin on acute blood pressure response to vasopressors in normotensive rats assessed with a bradykinin antagonist. J Cardiovasc Pharmacol. 1988 Jan;11(1):51–55. doi: 10.1097/00005344-198801000-00008. [DOI] [PubMed] [Google Scholar]
  3. Benetos A., Gavras H., Stewart J. M., Vavrek R. J., Hatinoglou S., Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension. 1986 Nov;8(11):971–974. doi: 10.1161/01.hyp.8.11.971. [DOI] [PubMed] [Google Scholar]
  4. Benetos A., Gavras I., Gavras H. Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension. 1986 Nov;8(11):1089–1092. doi: 10.1161/01.hyp.8.11.1089. [DOI] [PubMed] [Google Scholar]
  5. Carretero O. A., Scicli A. G. The renal kallikrein-kinin system. Am J Physiol. 1980 Apr;238(4):F247–F255. doi: 10.1152/ajprenal.1980.238.4.F247. [DOI] [PubMed] [Google Scholar]
  6. Crantz F. R., Swartz S. L., Hollenberg N. K., Moore T. J., Dluhy R. G., Williams G. H. Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension. Hypertension. 1980 Sep-Oct;2(5):604–609. doi: 10.1161/01.hyp.2.5.604. [DOI] [PubMed] [Google Scholar]
  7. Dixon C. M., Fuller R. W., Barnes P. J. The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects. Br J Clin Pharmacol. 1987 Jan;23(1):91–93. doi: 10.1111/j.1365-2125.1987.tb03015.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Erdös E. G. Angiotensin I converting enzyme. Circ Res. 1975 Feb;36(2):247–255. doi: 10.1161/01.res.36.2.247. [DOI] [PubMed] [Google Scholar]
  9. Ferner R. E., Simpson J. M., Rawlins M. D. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) 1987 May 2;294(6580):1119–1120. doi: 10.1136/bmj.294.6580.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fuller P. J., Funder J. W. The cellular physiology of glandular kallikrein. Kidney Int. 1986 May;29(5):953–964. doi: 10.1038/ki.1986.93. [DOI] [PubMed] [Google Scholar]
  11. Fuller R. W., Warren J. B., McCusker M., Dollery C. T. Effect of enalapril on the skin response to bradykinin in man. Br J Clin Pharmacol. 1987 Jan;23(1):88–90. doi: 10.1111/j.1365-2125.1987.tb03014.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Greene L. J., Camargo A. C., Krieger E. M., Stewart J. M., Ferreira S. H. Inhibition of the conversion of angiotensin I to II and potentiation of bradykinin by small peptides present in Bothrops jararaca venom. Circ Res. 1972 Sep;31(9 Suppl):62–71. [PubMed] [Google Scholar]
  13. Johnston C. I., Clappison B. H., Anderson W. P., Yasujima M. Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol. 1982 Apr 21;49(6):1401–1404. doi: 10.1016/0002-9149(82)90350-2. [DOI] [PubMed] [Google Scholar]
  14. Johnston C. I., Millar J. A., McGrath B. P., Matthews P. G. Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. Lancet. 1979 Sep 8;2(8141):493–496. doi: 10.1016/s0140-6736(79)91552-6. [DOI] [PubMed] [Google Scholar]
  15. Kaplan A. P., Austen K. F. A pre-albumin activator of prekallikrein. J Immunol. 1970 Oct;105(4):802–811. [PubMed] [Google Scholar]
  16. Kiowski W., van Brummelen P., Hulthén L., Amann F. W., Bühler F. R. Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther. 1982 Jun;31(6):677–684. doi: 10.1038/clpt.1982.95. [DOI] [PubMed] [Google Scholar]
  17. Levinsky N. G. The renal kallikrein-kinin system. Circ Res. 1979 Apr;44(4):441–451. doi: 10.1161/01.res.44.4.441. [DOI] [PubMed] [Google Scholar]
  18. Margolius H. S., Horwitz D., Geller R. G., Alexander R. W., Gill J. R., Jr, Pisano J. J., Keiser H. R. Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ Res. 1974 Dec;35(6):812–819. doi: 10.1161/01.res.35.6.812. [DOI] [PubMed] [Google Scholar]
  19. Margolius H. S. The kallikrein-kinin system and the kidney. Annu Rev Physiol. 1984;46:309–326. doi: 10.1146/annurev.ph.46.030184.001521. [DOI] [PubMed] [Google Scholar]
  20. McGiff J. C., Terragno N. A., Malik K. U., Lonigro A. J. Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res. 1972 Jul;31(1):36–43. doi: 10.1161/01.res.31.1.36. [DOI] [PubMed] [Google Scholar]
  21. Nishimura K., Alhenc-Gelas F., White A., Erdös E. G. Activation of membrane-bound kallikrein and renin in the kidney. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4975–4978. doi: 10.1073/pnas.77.8.4975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ogihara T., Maruyama A., Hata T., Mikami H., Nakamaru M., Naka T., Ohde H., Kumahara Y. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin Pharmacol Ther. 1981 Sep;30(3):328–335. doi: 10.1038/clpt.1981.168. [DOI] [PubMed] [Google Scholar]
  23. Ohman K. P., Karlberg B. E., Nilsson O. R., Wettre S. Captopril, aldosterone and urinary kallikrein in primary hypertension. Clin Exp Hypertens A. 1983;5(4):523–529. doi: 10.3109/10641968309081789. [DOI] [PubMed] [Google Scholar]
  24. Oparil S., Haber E. The renin-angiotensin system (first of two parts). N Engl J Med. 1974 Aug 22;291(8):389–401. doi: 10.1056/NEJM197408222910805. [DOI] [PubMed] [Google Scholar]
  25. Plummer T. H., Jr, Kimmel M. T. An improved spectrophotometric assay for human plasma carboxypeptidase N1. Anal Biochem. 1980 Nov 1;108(2):348–353. doi: 10.1016/0003-2697(80)90598-9. [DOI] [PubMed] [Google Scholar]
  26. Quilley J., Duchin K. L., Hudes E. M., McGiff J. C. The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kallikrein-kinin system. J Hypertens. 1987 Feb;5(1):121–128. doi: 10.1097/00004872-198702000-00017. [DOI] [PubMed] [Google Scholar]
  27. Sealey J. E., Atlas S. A., Laragh J. H., Oza N. B., Ryan J. W. Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin. Nature. 1978 Sep 14;275(5676):144–145. doi: 10.1038/275144a0. [DOI] [PubMed] [Google Scholar]
  28. Sheikh I. A., Kaplan A. P. Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochem Pharmacol. 1986 Jun 15;35(12):1957–1963. doi: 10.1016/0006-2952(86)90727-6. [DOI] [PubMed] [Google Scholar]
  29. Swartz S. L., Williams G. H., Hollenberg N. K., Levine L., Dluhy R. G., Moore T. J. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest. 1980 Jun;65(6):1257–1264. doi: 10.1172/JCI109788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Textor S. C., Brunner H. R., Gavras H. Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism. Hypertension. 1981 Mar-Apr;3(2):269–276. doi: 10.1161/01.hyp.3.2.269. [DOI] [PubMed] [Google Scholar]
  31. Vavrek R. J., Stewart J. M. Competitive antagonists of bradykinin. Peptides. 1985 Mar-Apr;6(2):161–164. doi: 10.1016/0196-9781(85)90033-6. [DOI] [PubMed] [Google Scholar]
  32. Vinci J. M., Horwitz D., Zusman R. M., Pisano J. J., Catt K. J., Keiser H. R. The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension. 1979 Jul-Aug;1(4):416–426. doi: 10.1161/01.hyp.1.4.416. [DOI] [PubMed] [Google Scholar]
  33. Waeber G., Fasanella d'Amore T., Nussberger J., Waeber B., Brunner H. R. Effect on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A. Eur J Clin Pharmacol. 1987;31(6):643–646. doi: 10.1007/BF00541289. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES